A MAP to the Future of Targeted Oncology
The latest in our series of healthcare analyst reports focuses on the mitogen-activated protein kinase (MAPK) pathway, one of the most commonly perturbed signaling pathways in human cancer. Flowing from RAS to RAF to MEK to EKR, the pathway is a master regulator of cell growth and survival. Therefore, the amplification of proteins or mutation of key signaling domains are a common hallmark of cancer.
Several approved drugs targeting this pathway have posted impressive revenue, and recent and upcoming data is shaping the competitive landscape of this space.
PETER BAK, PHD
Managing Director
Back Bay Life Science Advisors
GEIR H. HOLOM, PHD, MD
Senior Equity Analyst, Healthcare
DNB Carnegie
ANNA URREA
Senior Analyst
Back Bay Life Science Advisors
About the DNB Carnegie | Back Bay Partnership for Healthcare
From private and emerging public life science and healthcare companies seeking partnering, licensing, and M&A opportunities to listing and executing on US and Nordic exchanges to consolidators seeking and executing acquisitions and other growth strategies, DNB Carnegie | Back Bay provides financial and strategic guidance on growth opportunities across sector and stage.
Our healthcare strategy and banking teams span the globe and have worked across every stage and sector of healthcare development.
Learn more about our partnership and read our disclosures.